Quintiles said that the new wholly owned facility has expanded testing capabilities with an initial focus on safety testing. The lab started receiving and testing clinical trial samples on March 1, and has already received National Glycohemoglobin Standardisation Program Level 1 certification for diabetes testing.
Reportedly, the new Japan lab is taking steps toward certification by the College of American Pathologists (CAP). The network recently expanded its anatomical pathology capability in China.
Alan Ong, vice president and general manager of global central laboratories in Asia at Quintiles, said: “The growth of clinical research in Asia-Pacific is driving this move as we continue to reduce complexity and help our customers get new medicines to patients faster. We are building on a strong record of high quality and outstanding customer service, and with an expanding test menu, it makes sense to move into new facilities that provide room for growth.”